IRA THREATENS CURES FOR PEOPLE WITH DIABETES

Study Shows Government-Mandated Drug Pricing Policies Decimate Development of Drugs Treating Diabetes

A new study by research firm Vital Transformation estimates that there would be hundreds of lost therapies, including those for patients battling diabetes, if Congress expands new aggressive government-mandated drug pricing policies.

"PILL PENALTY" THREATENS DEVELOPMENT OF DIABETES CURES

The new IRA law discourages the development of medicines that come in pill or tablet form, often referred to as "small molecule medicines." For diabetes treatment, insulin was originally approved and regulated as a small molecule, and is crucial to the present and future management of this chronic condition.¹ In addition to small molecules offering patients better affordability and mobility, they are also central to ongoing research for diabetes treatment and drug development. 70% of all currently available medicines – treatments Americans rely on every day – would likely never have been created, including nearly a dozen different treatments for metabolic and other conditions that overlap with diabetes issues.


LOST THERAPIES

8.5

LOST INNOVATION



237 fewer medicines will be FDA-approved over the next decade, especially in chronic areas where we are desperately seeking cures and chronic relief – like diabetes.





IRA THREATENS CURES FOR PEOPLE WITH DIABETES





IRA THREATENS FUTURE OF DIABETES INNOVATION WITH HEAVY-HANDED APPROACH

The population of patients with diabetes is massive: **More than 6.1 million people** will receive treatment for related indications in the coming years, according to Vital Transformation's analysis. But the Inflation Reduction Act's Medicare price setting and other looming financial limits mean patients will face an uncertain future with significant cuts in investment and innovation toward treating their disease. In fact, **four of the first 10 drugs subject** to IRA price setting are used to treat diabetes or related conditions. Research shows the government's mandated prices will ultimately cost patients and have a chilling effect on the viability of diabetes disease research and treatment development.

WHAT THEY'RE SAYING ABOUT INVESTMENTS

"I'm really worried about the harm this will do to new cures and possibilities in medicine." – Eli Lilly CEO David Ricks² "This investment in additional research and development in products like Jardiance is at risk due to the flawed price-controlling measures of the IRA." - Boehringer Ingelheim³

LEARN MORE

The new study issued by We Work For Health (WWFH) and Vital Transformation modeled the impacts on industry revenues, jobs and future research and development investments. For the full study, please visit <u>We Work For Health</u>.

- 1. Campbell, A. Biologic, Small Molecule, and Biosimilar Drugs: What's the Difference? diabetesselfmanagement.com. 2022 April 19.
- 2. Constantino, A.K. Eli Lilly CEO says Medicare price negotiations could harm drug development. CNBC. 2023 June 13.
- 3. Boehringer Ingelheim. <u>Statement</u> by Boehringer Ingelheim on selection of Jardiance (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program. 2023 Aug 29.